Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Physiomics Plc

Healthcare GB PYC

0.6GBX
-0.025(4.00%)

Last update at 2026-06-05T14:06:00Z

Day Range

0.600.65
LowHigh

52 Week Range

0.250.80
LowHigh

Fundamentals

  • Previous Close 0.62
  • Market Cap2.15M
  • Volume4511648
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.52333M
  • Revenue TTM1.01M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM -0.51308M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.45727M -0.66875M -0.57201M -0.35897M -0.33693M
Minority interest - - - - -
Net income -0.41525M -0.60935M -0.47726M -0.25314M -0.21583M
Selling general administrative 0.01M 0.01M - - -
Selling and marketing expenses - - - - -
Gross profit -0.43508M -0.67743M 0.60M 0.83M 0.70M
Reconciled depreciation 0.00906M 0.00895M 0.01M 0.01M 0.01M
Ebit -0.45727M -0.66875M -0.57373M -0.35911M -0.33704M
Ebitda -0.44821M -0.65980M -0.56329M -0.34798M -0.32462M
Depreciation and amortization 0.00906M 0.00895M 0.01M 0.01M 0.01M
Non operating income net other - - - - -
Operating income -0.45779M -0.67082M -0.57373M -0.35911M -0.33704M
Other operating expenses 1.29M 1.24M 1.17M 1.19M 1.04M
Interest expense 0.00000M 0.00003M - 0.00014M 0.00011M
Tax provision -0.04201M -0.05940M -0.09475M -0.10583M -0.12110M
Interest income 0.00052M 0.00210M 0.00172M 0.00014M 0.00011M
Net interest income 0.00052M 0.00206M 0.00172M 0.00014M 0.00011M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.04201M -0.05940M -0.09475M -0.10583M -0.12110M
Total revenue 0.78M 0.54M 0.60M 0.83M 0.70M
Total operating expenses 0.02M 0.02M 1.17M 1.19M 1.04M
Cost of revenue 1.27M 1.22M - - -
Total other income expense net 0.00052M 0.00206M 0.00172M 0.00014M 0.00011M
Discontinued operations - - - - -
Net income from continuing ops -0.41525M -0.60935M -0.47726M -0.25314M -0.21583M
Net income applicable to common shares - - -0.47726M -0.25314M -0.21583M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 0.89M 0.42M 0.67M 1.12M 1.32M
Intangible assets 0.00328M 0.00438M 0.00548M 0.00300M 0.00344M
Earning assets - - - - -
Other current assets 0.05M 0.06M - 0.41M 0.26M
Total liab 0.20M 0.14M 0.14M 0.14M 0.16M
Total stockholder equity 0.69M 0.28M 0.53M 0.97M 1.17M
Deferred long term liab - - - - -
Other current liab 0.09M 0.08M 0.12M 0.11M 0.14M
Common stock 1.21M 0.54M 0.39M 0.39M 0.39M
Capital stock 1.21M 0.54M 0.39M 0.39M 0.39M
Retained earnings -7.81334M -7.42626M -6.83551M -6.52643M -6.27329M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00018M 0.00040M -
Cash 0.46M 0.19M 0.42M 0.69M 1.04M
Cash and equivalents - - - - -
Total current liabilities 0.20M 0.14M 0.14M 0.14M 0.16M
Current deferred revenue - 0.03M - - -
Net debt -0.46124M -0.19107M -0.41659M -0.68767M -1.04345M
Short term debt - 0.00382M - - -
Short long term debt - - - - -
Short long term debt total - 0.00382M - - -
Other stockholder equity 6.27M 6.12M 6.98M 7.11M 7.05M
Property plant equipment - - 0.00776M 0.01M 0.02M
Total current assets 0.88M 0.40M 0.66M 1.10M 1.30M
Long term investments - - - - -
Net tangible assets - - 0.53M 0.97M 1.16M
Short term investments - - - - -
Net receivables 0.36M 0.15M 0.03M 0.08M 0.16M
Long term debt - - - - -
Inventory - 0.04M - - -
Accounts payable 0.09M 0.03M 0.02M 0.03M 0.02M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.02M 1.04M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.39M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.00018M 0.00040M -
Deferred long term asset charges - - - - -
Non current assets total 0.02M 0.02M 0.01M 0.02M 0.02M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.00341M -0.01521M -0.00449M -0.00923M -0.01604M
Change to liabilities - - 0.00206M -0.01696M 0.03M
Total cashflows from investing activities -0.00341M -0.01521M -0.00449M -0.00923M -0.01604M
Net borrowings - - - - -
Total cash from financing activities 0.82M 0.34M - 0.00284M 0.04M
Change to operating activities - - - - -
Net income -0.41525M -0.60935M -0.47726M -0.25314M -0.21583M
Change in cash 0.27M -0.22552M -0.27108M -0.35578M -0.00441M
Begin period cash flow 0.19M 0.42M 0.69M 1.04M 1.05M
End period cash flow 0.46M 0.19M 0.42M 0.69M 1.04M
Total cash from operating activities -0.54614M -0.54813M -0.26659M -0.34939M -0.03261M
Issuance of capital stock 0.91M 0.38M 0.00000M 0.00284M 0.04M
Depreciation 0.00906M 0.00895M 0.01M 0.01M 0.01M
Other cashflows from investing activities 0.00052M 0.00210M 0.00172M 0.00014M 0.00011M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.22177M -0.00111M 0.15M -0.16321M 0.16M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.08669M -0.04265M -0.00449M -0.00923M -0.01604M
Change to netincome - - 0.04M 0.07M -0.01538M
Capital expenditures 0.00394M 0.02M 0.00664M 0.00937M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.16199M -0.00370M 0.16M -0.18017M 0.19M
Stock based compensation 0.00517M 0.02M 0.03M 0.06M 0.02M
Other non cash items 0.02M 0.03M -0.00172M 0.01M -0.00011M
Free cash flow -0.55008M -0.56544M -0.27322M -0.35876M -0.04876M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PYC
Physiomics Plc		 -0.025 4.00% 0.60 - 6.17 2.14 5.25 1.89 -8.7624
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.

Physiomics Plc

Milton Park Innovation Centre, Oxford, United Kingdom, OX14 4RY

Key Executives

Name Title Year Born
Dr. James Simon Millen CEO & Exec. Chairman 1969
Dr. Christophe D. Chassagnole Ph.D. COO & Exec. Director NA
Prof. David Fell Co-Founder & Member of Scientific Advisory Board NA
Mr. Anthony Louis Clayden ACA, BSc (Hons), MSI Head of Fin. & Company Sec. 1968
Ms. Charmaine Fraser Admin. Mang. NA
Ms. Hayley Close Head of Bus. Devel. NA
Dr. Mark Middleton M.D., Ph.D. Consultant & Member of Scientific Advisory Board NA
Dr. Robert Jackson Ph.D. Consultant & Member of Scientific Advisory Board 1944
Dr. Peter Joseph Sargent CEO, COO & Director 1978
Mr. Anthony Louis Clayden ACA, BSc (Hons), MSI Head of Finance & Company Secretary 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions